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Aims: It has been recommended that the percentage of high-grade (HG) Gleason patterns 4 
and 5 should be quantified in prostate cancer. However, this has not been assessed in a cohort 
using prostate cancer death as an outcome, and there is debate as to whether the biopsy with 
the ‘worst’ percentage of HG disease or an ‘overall’ percentage of HG disease should be 
reported. Such data may assist in active surveillance decisions. 
Methods and results: Men with clinically localised prostate cancer diagnosed by needle 
biopsy from 1990 to 2003 were included. The endpoint was prostate cancer death. Clinical 
variables included Gleason score (GS), prostate-specific antigen level, age, clinical stage, and 
disease extent. Deaths were divided into those from prostate cancer and those from other 
causes, according to World Health Organization criteria. Nine hundred and eighty-
eight biopsy cases were centrally reviewed according to criteria agreed at the 
Chicago International Society of Urological Pathology conference in 2014. Cores were given 
individual GSs and Grade Groups (GGs), and a percentage of each grade was given for each 
core. Both the worst percentage of HG disease seen in a biopsy series and overall percentage 
of HG disease were calculated. The overall percentage of HG disease was highly 
significant, with a hazard ratio of 4.45 for the interquartile range (95% confidence 
interval 3.30–6.01, P < 2.2 × 10–16), and was similar to the percentage of HG disease seen in 
the worst core. In multivariate analysis, both were highly significant. GG2 cases with ≤5% 
Gleason pattern 4 showed similar survival to GG1 cases.  
Conclusions: These data validate the use of percentage of HG disease to predict prostate 
cancer death. As both worst and overall percentage of HG disease are powerful predictors of 
outcome, either could be chosen to provide prognostic information. 
  
Introduction 
Gleason grading of prostate cancer has been established for >40 years.1 Although the 
basic grading categories have remained unchanged during this time, there have been 
numerous changesin the methodologies used to determine the Gleason score (GS) of prostate 
cancer over that period. At the 2014 International Society of Urological Pathology 
(ISUP) Chicago conference,the concept of Grade Groups (GGs) was accepted by a broad 
range of clinicians and pathologists, stratifying Gleason patterns into five separate 
prognostic GGs.2,3 These groupings have been validated in large radical prostatectomy 
cohorts, in biopsy-based cohorts treated with radiation, and also in a cohort of conservatively 
treated prostate cancers.4 
However, at this meeting there was also a consultation on the reporting of the 
percentage of high-grade (HG) disease and the assignment of a GG. The reporting 
of HG disease was first suggested >20 years ago,5 and a number of other articles have 
suggested that it is of clinical use in predicting biochemical relapse after radical 
prostatectomy6–8 or in predicting prostate cancer death after transurethral resection of the 
prostate (TURP).9 Recently, an exceptionally large cohort of 12 823 consecutive patients and 
of 2971 matched preoperative biopsies was used to validate the importance of assigning the 
percentage of Gleason pattern 4 and 5 with biochemical relapse.10 This has been validated in a 
number of other studies,11,12 and it has been suggested, for instance, that the percentage of 
grade 4 may be used to determine criteria for active surveillance in those with minimal grade 
4 disease.13,14 
However, there has been no study examining the utility of assessing the 
percentages of Gleason patterns 4 and 5 in prostate biopsies and their correlation with 
prostate cancer death. 
The assignation of a GS may have considerable effects on patient management, and 
there is significant intraobserver variation in some areas.15,16 In most 
centres, active surveillance may be given only to patients with GG1 tumours. However, GG2 
includes a spectrum of disease, from patients with minimal HG tumour, to those in which up 
to 49% is HG. It is possiblethat many of those patients with a small amount of 
Gleason pattern 4 may be also managed more conservatively. 
A potential problem with assessing HG disease is whether to measure the percentage 
of HG disease on the ‘worst’ core or whether to make an ‘overall’ assessment of the 
percentage based on the cancer in all cores. 
In this study, we examined the risk of prostate cancer death relative to the 
percentages of both Gleason pattern 4 and Gleason pattern 5 in a biopsy series treated 
conservatively and previously validated for the GGs. 
We hypothesised that calculation of the percentage of HG disease could add 
prognostic information beyond that provided by standard clinicopathological parameters. 
  
Materials and methods 
PATIENTS 
Cases of prostate cancer were identified from three cancer registries in Great Britain. Within 
each region, collaborating hospitals were sought, and cases from these hospitals were 
reviewed. Men were included in this study if they were aged <76 years at the date of 
diagnosis and had clinically localised prostate cancer diagnosed by needle biopsy in 1990–
2003 inclusive. The median date of diagnosis was May 2002. Patients treated with radical 
prostatectomy or radiation therapy within 6 months of diagnosis were excluded. This was a 
practical measure to ensure that all men were not initially treated with radical therapy. Only 
initial hormone therapy was permitted. In addition, those with objective evidence 
of metastatic disease (by bone scan, X-ray, radiograph, computed tomography scan, magnetic 
resonance imaging, bone biopsy, lymph node biopsy, or pelvic lymph node dissection) or 
clinical indications of metastatic disease (including pathological fracture, soft tissue 
metastases, spinal compression, or bone pain), or a prostate-specific 
antigen (PSA) measurement of >100 ng/ml at or within 6 months of diagnosis, were also 
excluded. Men who had received hormone therapy prior to the diagnostic biopsy were also 
excluded, because of the influence of hormone treatment on Gleason pattern. We also 
excluded men who died within 6 months of diagnosis or had <6 months of follow-up. 
Original histological specimens from the diagnostic procedure were requested and 
centrally reviewed by a panel of three expert urological pathologists to confirm the diagnosis 
of adenocarcinoma and to reassign GSs by using a contemporary and consistent 
interpretation of the Gleason scoring system.17,18 For each core in every case, when cancer was 
present, percentages of Gleason pattern 3, Gleason pattern 4 and Gleason pattern 5 
were given, and a total tumour length was given for each core. Stromal gaps were not 
deducted from the total length measurements. An overall GS was given on the basis of the 
whole series, and the worst GS seen in a core as published previously.4 
The panel met and discussed all controversial cases and a selection of others to audit 
the dataset. In keeping with the ISUP Chicago conference and the grading in World Health 
Organization (WHO) 2016, cribriform and glomeruloid glands were all assigned Gleason 
pattern 4. Follow-up was conducted by use of the cancer registries, and the cut-off date 
was 31 December 2012. Deaths were divided into those from prostate cancer and those from 
other causes, according to WHO standardised criteria (WHO, 2010). National ethics approval 
was obtained from the Northern Multicentre Research Ethics Committee, and local ethics 
committee approval was obtained at each of the collaborating hospitals. 
  
STATISTICAL ANALYSIS 
Survival analysis was performed with a Cox proportional hazards model. The primary 
endpoint was time to death from prostate cancer. All events were used for 
estimation of hazard ratios(HRs), and observations were censored on the date of last follow-
up or death from other causes. Covariates included in the statistical analysis were GGs by 
worst and overall grade, the percentage of HG disease overall and in the worst core, baseline 
PSA level, extent of disease calculated from the percentage of positive cores, T stage, 
hormone treatment, and patient age.The baseline PSA level was defined as the last 
prediagnostic PSA measurement within 6 months before diagnosis. If no such PSA value was 
available, we took the first postdiagnostic PSA level within 6 months; failing that, the 
prediagnostic PSA level measured closest to the date of diagnosis was used. All PSA values 
after treatment with hormones or orchiectomy or within 3 weeks after a surgical 
procedure on the prostate were excluded. 
The PSA level was modelled as the natural logarithm of [1 + PSA (ng/ml)]. Patients 
with values of >100 ng/ml were excluded as likely to have metastatic disease. 
Missing PSA values were imputed by use of a median regression with GS, age and 
extent of disease as predictors, and PSA as outcome. Missing T stage values were 
imputed using the median clinical T stage among all patients. A multivariate Cox 
proportional hazard model applied performed with overall GG, worst GG, overall percentage 
of HG disease, worst core percentage of HG disease, baseline PSA level, extent of disease, 
T stage, hormone treatment and patient age as predictors. The primary event of interest was 
time to death from prostate cancer. A stepwise model selection was performed. 
Spearman’s rank correlation was estimated between all variables. All applied tests 
were two-sided, and P-values of <0.05 were accepted as statistically significant. No P-
value adjustment was performed for multiple comparisons. Statistical analyses 
were performed with r (R Core Team (2018). R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-
project.org/). 
Observations were censored on the date of last follow-up, or death from other 
causes. All events were used for estimation of HRs (maximum follow-up 232 months), but 
follow-up was censored at 10 years for prediction of 10-year risks. HRs were calculated for 
the interquartile range (IQR), as this is a better method of comparison when the units of the 
different variables are very different. 
Analysis was repeated with exclusion of cases with Gleason pattern 5 and 
examination of only the percentage of Gleason pattern 4 in GG2 and GG3 for both overall 
and worst models. 
  
Results 
Six thousand five hundred and one cores from 988 individual cases were evaluated. One 
hundred and sixty-nine patients (17.1% of the cohort) died from prostate cancer. The mean, 
median and IQR of patient age, number of cores sampled, serum PSA level and percentage of 
cores involved, T stage, hormonal treatment and the overall and worst percentage 
of HG disease areshown in Table 1. 
For the overall core calculation, the HR for the IQR in overall HG disease 
was 4.45 [95% confidence interval (CI) 3.30–6.01; P < 2.2 × 10–16]. Harrel’s C-statistic 
was 0.733. This was extremely similar to the results obtained when the percentage 
of HG disease in the worst core was used (HR = 6.34; 95% CI 4.29–9.39; P < 2 × 10–
16). Harrel’s-C statistic was 0.727. The IQR HRs are shown in Table 2. 
A multivariate model was constructed by the use of backward selection, starting with 
a candidate set of variables consisting of all nine predictors (the ‘full model’), and with the 
Wald chi-square P-values of the individual factors, with a significance level of 0.05 as a rule 
for staying in the final model (Table 3). In the final reduced model, the overall 
percentage of HG disease outperformed the other variables (HR = 2.84, 95% CI 2.00–
4.03), followed by extent of disease, clinical stage of disease, and serum PSA level. A 
further analysis comparing the final model with and without overall percentage of HG disease 
confirmed that this predictor contributed significantly to the model fit (P < 0.001). 
A Spearman’s correlation between all nine fitted predictors in the full Cox 
proportional hazard model showed a very strong correlation between all of the different 
pathological measures of grade, but a weak correlation between age at diagnosis and all other 
predictors (Figure 1). 
The repeat of the analysis on GG2 and GG3 alone showed that the overall percentage 
of Gleason pattern 4 disease remained a significant predictor of prostate cancer death in the 
multivariate model (Table 4). The risk of prostate cancer death in the whole cohort and 
limited to GG2 and GG3 is shown in Figure 2A,B. 
When cut-offs of <25%, 25% to <50% and >50% Gleason pattern 4 disease were 
used, three separate cohorts were formed (Figure 3A). The use of an alternative 5% cut-off 
for Gleason pattern 4 disease in GG2 resulted in comparable survival 
to the GG1 cohort (Figure 3B). 
  
Discussion 
Assessment of the percentage of Gleason patterns 4 and 5 in prostate biopsies has huge 
potential to assist in decision-making prior to patient treatment. Previous studies have shown 
the power of this assessment to predict biochemical relapse after radical prostatectomy, and 
also prostate cancer death after TURP. However, none of these studies addressed the most 
pressing questions for clinicians and patients immediately after prostate cancer diagnosis on 
biopsy: whether to treat the patient with a radical method or to allow active surveillance. 
Active surveillance is usually limited to GS 3 + 3 = 6 (GG1) patients; however, GS 3 + 4 = 7 
(GG2) patients also have a very good prognosis. Our study shows that this is especially true 
of those with minimal Gleason pattern 4 disease. 
There exists, and will continue to exist, intraobserver error in Gleason scoring15,16; a 
relatively large population of GS 3 + 4 = 7 patients (GG2) are often treated radically, when 
many have a very good outcome with active surveillance. 
It is often difficult for pathologists to give an opinion on reporting very minor small 
areas of Gleason pattern 4.  Borderline decisions may mean that the change from GG1 
to GG2may lead to entirely different treatments. Reporting the percentage 
of HG disease allows the clear differentiation of cases in which only minor elements of HG 
disease are identified fromthose cases that possibly verge on a GS of 4 + 3 = 7 (GG3), which 
has been shown to indicate a much worse prognosis. Such reporting will enable trials and 
investigations into the active surveillance of a selected group of men with GG2 disease, 
below a certain percentage threshold. 
The methodology to be used for providing a percentage of HG disease is 
contentious. The use of an overall or worst GS has previously been extensively debated in 
the literature.19–21There is great variability in how GS is assigned in different centres and how 
it is interpreted by clinicians.22 Some have advocated assigning a GS to every core and giving 
no overall score for the case. Other pathologists give a GS per submitted specimen pot, which 
might include more than one core.15 
In this study, we uniquely assessed both global and worst core methods of assigning 
percentage of HG disease in relation to prostate cancer death in a large univariable and 
multivariable analysis with other prognostic pathological parameters. 
This has shown, similarly to our findings in the same cohort on GGs,4 that both 
methodologies provide highly significant results, and that the overall percentage of 
HG disease outperforms the percentage in the worst core both in the overall cohort and in 
GG2 and GG3, where it is likely to be of more clinical significance. A variety of methods 
have been suggested for the calculation of the percentage of HG disease in routine 
reports10,23,24 and on the practical problems that it entails.25 
The strengths of this study include the large sample size and detailed nature of 
the centralised pathological review and long-term follow-up. In some series, it is unclear 
whether individual cores have been separately graded, especially when they are processed 
within one cassette or slide. 
The weaknesses of the study include its retrospective nature, and the criticism that 
prostate cancer is now treated differently than it was 10 years ago. The majority of the 
cohort arefrom sextant biopsies, and performance of these is not contemporary 
practice. This is an axiomatic weakness of retrospective prostate studies, to allow time to 
utilise prostate cancer death as an outcome. Even in large prospective trials such as 
PROTECT,26 the biopsy methods are now considered to have resulted in undersampling of 
potential disease. 
In this study, we did not address the significance of different patterns of HG disease,27–
29 but acknowledge that this is of great interest, and hope to address it in this cohort in a 
future study. 
We have validated, for the first time, the considerable power of assessments of the 
percentage of HG disease and Gleason pattern 4 to predict prostate cancer death. We 
recommend that assessments of HG disease be made mandatory in datasets, as they may 
significantly impact on treatment options after biopsy. The preferred methods of assessment 
will need consensusin the international pathological community in order to optimise 
treatment choices. 
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Figure 1. Spearman’s correlation between all nine fitted predictors from the full Cox 
proportional hazard regression model. GG, Grade Group; HGwPC100, worst core high-
grade disease (%); (%)ovHG100, overall high-grade (%) disease; WG, worst grade. 
  
Figure 2. A, Percentage of high-grade disease overall versus 10-year survival. B, Percentage 
of Gleason pattern 4 overall in overall Grade Groups 2 and 3 versus 10-year survival. 
  
Figure 3. A, Kaplan–Meier (KM) curves showing a clear separation of Grade Groups 2 and 3 
into three separate groups based on practical percentage values. B, KM curve showing no 
separation between Grade Group 1 and Grade Group 2 with a cut-off of 5% 
of Gleason pattern 4 disease 
 
 
 
  
 
 
 
 
 
Table 1. Candidate diagnostic factors in the derivation and validation datasets (N = 988) 
Variable name Variable Definition/units Median (IQR), or n (%) 
Patient age Age Years 70.90 (66.69–73.65) 
Overall GG GG1 GS of 3 + 3 = 6 307 (31.1) 
  GG2 GS of 3 + 4 = 7 303 (30.7) 
  GG3 GS of 4 + 3 = 7 210 (21.3) 
  GG4 GS of 8 56 (5.7) 
  GG5 GS of 9 or 10 112 (11.3) 
Worst GG WGG1 – 307 (31.1) 
  WGG2 – 244 (24.7) 
  WGG3 – 206 (20.9) 
  WGG4 – 111 (11.2) 
  WGG5 – 120 (12.1) 
PSA PSA* ng/ml 14.3 (8.1–31.0) 
Extent of disease Extent % of positive cores 5.0 (2.5–8.3) 
Clinical T stage Stage† cT1–cT2 842 (85.2) 
    cT3 or higher 146 (14.8) 
Hormone treatment Hormones Yes 574 (58.1) 
Overall high-grade 
disease (%) 
ovHG100 – 26.2 (0.0, 70.0) 
Worst core high-
grade disease (%) 
HGwPC100 – 40.0 (0.0–90.0) 
GG, Grade Group; GS, Gleason score; IQR, interquartile range; PSA, prostate-specific 
antigen; WGG, worst Grade Group. 
*Missing PSA values (n = 3) were imputed by use of a median regression with GS, age 
and extent of disease as predictors, and PSA as an outcome. 
†Missing T stage values (n = 230) were imputed by median of observed values T1–T2 stage. 
  
Table 2. Univariate Cox proportional hazard regression model (N = 988, no. of deaths = 169) 
Predictor IQR HR (95% CI) LR χ₁² P-value C-
index 
Overall grade group (linear) 3.06 (2.48–3.78) 102.842 <2.2 × 10–16 0.732 
Worst grade group (linear) 3.03 (2.44–3.77) 101.322 <2.2 × 10–16 0.730 
Overall high grade (%) 4.45 (3.30–6.01) 100.709 <2.2 × 10–16 0.733 
Worst core high grade (%) 6.34 (4.29–9.39) 99.866 <2.2 × 10–16 0.727 
Extent of disease (% positive cores) 3.73 (2.75–5.04) 78.437 <2.2 × 10–16 0.704 
Log(1 + PSA) 2.52 (2.00–3.18) 61.152 5.33 × 10–15 0.686 
Stage (stage = 3) 3.70 (2.68–5.12) 51.815 6.10 × 10–13 0.612 
Hormones (yes) 3.28 (2.26–4.74) 47.616 5.18 × 10–12 0.638 
Age 1.21 (0.98–1.51) 3.165 0.075 0.527 
C-index, Harrell’s C-index; CI, confidence interval; HR, hazard ratio; IQR, interquartile 
range; LR χ₁², likelihood ratio test (d.f. = 1); PSA, prostate-specific antigen. 
  
  
Table 3. Multivariate Cox proportional hazard regression model (N = 988, 
no. of deaths = 169) 
  Full multivariable 
model (all nine predictors) 
Final model* 
Predictor IQR HR (95% CI) Wald χ₁² (P-value) IQR HR 
(95% CI) 
Wald χ₁² 
(P-value) 
Overall grade groups (linear) 1.70 (0.61–4.74) 1.035 (0.309) – – 
Worst grade group (linear) 0.72 (0.21–2.43) 0.288 (0.592) – – 
Overall high grade (%) 1.89 (0.70–5.10) 1.571 (0.210) 2.84 (2.00–
4.03) 
34.371 
(4.5 × 10–9) 
Worst core high grade (%) 1.21 (0.26–5.61) 0.056 (0.813) – – 
Extent of disease 
(% of positive cores) 
1.65 (1.14–2.40) 6.975 (0.008) 1.81 (1.26–
2.58) 
10.595 
(0.001) 
Log(1 + PSA) 1.30 (0.98–1.72) 3.412 (0.065) 1.36 (1.04–
1.79) 
4.948 
(0.026) 
Stage (stage = 3) 1.52 (1.06–2.17) 5.220 (0.022) 1.58 (1.11–
2.26) 
6.300 
(0.012) 
Hormones (yes) 1.40 (0.92–2.14) 2.498 (0.114) – – 
Age 1.06 (0.85–1.31) 0.268 (0.605) – – 
LR χ₁² (d.f., P-value) 147.318 (9, <2.2 × 10–16) 142.6 (4, <2.2 × 10–16) 
Harrell’s C-index (95% CI) 0.771 (0.724–0.817) 0.767 (0.721–0.814) 
CI, confidence interval; HR, hazard ratio; IQR, interquartile range; LR χ₁², likelihood ratio 
test; PSA, prostate-specific antigen. 
Wald χ₁² (d.f. = 1) for each model coefficient. 
*The final model was selected by the use of backward variable selection with Wald chi-
square P-values of individual factors and with a 5% significance level rule for staying in the 
final model. The same model was selected by forward stepwise variable selection. 
  
Table 4. Univariate and multivariate Cox proportional hazard regression model in Grade 
Groups 2 and 3 (N = 513, no. of deaths = 91) 
  Univariate analyses Final multivariate model 
Predictor IQR HR 
(95% CI) 
LR χ₁² 
test 
P-value C-index (95% 
CI) 
IQR HR 
(95% 
CI) 
Δχ₁² P-value 
T-stage 2.749 
(1.729–
4.370) 
15.463 8.41 × 10–
5 
0.581 (0.544–
0.619) 
1.915 
(1.164–
3.151) 
15.463 8.41 × 10–
5 
Extent of disease 
(% positive 
cores) 
2.090 
(1.426–
3.063) 
14.985 0.0001 0.634 (0.570–
0.698) 
1.698 
(1.142–
2.525) 
7.942 0.0048 
Worst core high 
grade (%) 
1.929 
(1.327–
2.804) 
12.081 0.0005 0.612 (0.548–
0.675) 
– – – 
Hormones (yes) 2.235 
(1.357–
3.681) 
11.371 0.0007 0.586 (0.532–
0.640) 
– – – 
Overall high 
grade (%) 
1.720 
(1.236–
2.392) 
10.181 0.0014 0.611 (0.547–
0.675) 
1.507 
(1.064–
2.134) 
5.269 0.0217 
Log(1 + PSA) 1.555 
(1.123–
2.153) 
7.139 0.0075 0.600 (0.535–
0.664) 
– – – 
Age 1.078 
(0.804–
1.444) 
0.254 0.6142 0.509 (0.445–
0.573) 
– – – 
  LR test (d.f., P-
value) = 28.675 (3, 2.62 × 10–
6) 
Harrell’s C-index 
(95% CI) = 0.677 (0.613–
0.741) 
C-index, Harrell’s C-index; CI, confidence interval; HR, hazard ratio; IQR, interquartile 
range; LR χ₁², likelihood ratio chi-square test (d.f. = 1); PSA, prostate-specific antigen. 
IQR HRs were used for continuous predictors, and HRs were used for categorical predictors. 
 
 
 
  
 
 
 
 
 
 
